Tarsier Pharma is developing Dazdotuftide (TRS), a bio-inspired therapeutic platform that targets autoimmune and inflammatory ocular diseases by re-engineering the immune response. Their lead candidate, TRS01, is currently in Phase 3 clinical trials for treating non-infectious anterior uveitis, a condition that can lead to vision loss if not promptly addressed.
Funding
$2.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Autoimmune and inflammatory ocular diseases, such as uveitis, pose a significant threat to vision, potentially leading to blindness if not promptly and effectively treated. Current treatments often involve steroids, which can have undesirable side effects, especially with long-term use. There is a need for steroid-free, targeted therapies that can effectively control ocular inflammation without the associated risks.
Solution
Tarsier Pharma is developing Dazdotuftide (TRS), a bio-inspired therapeutic platform designed to address autoimmune and inflammatory ocular diseases by modulating the immune response. The lead candidate, TRS01, is a steroid-free eye drop formulation in Phase 3 clinical trials for treating non-infectious anterior uveitis, including uveitic glaucoma. TRS01 aims to provide a local, effective, and safe treatment option, offering a promising profile for patients with ocular inflammatory diseases.
Target Audience
The primary target audience includes patients with non-infectious anterior uveitis, including those with uveitic glaucoma, and the ophthalmologists and specialists who treat these conditions.
Features
- Bio-inspired therapeutic platform targeting inflammatory diseases from within the immune system
- Patented, proprietary new molecule designed to 're-engineer' the immune system
- TRS01: Steroid-free eye drop formulation for local treatment of non-infectious anterior uveitis and uveitic glaucoma
- Phase 3 clinical trials underway evaluating the safety and efficacy of TRS01 compared to standard-of-care steroid eye drops
- Potential to effectively control a range of autoimmune and inflammatory ocular diseases